Skip to main content


Health

Novartis says that it now seeks approval for serelaxin. Researchers say that in a study of 1,161 patients, the drug cut deaths from any cause at six months by 37 percent and led to a marked reduction in worsening of heart failure during hospitalization.
839 of 1826




Newsletter Sign Up



Daily Readings

Reading 1, Colossians 1:1-8
From Paul, by the will of God an apostle of Christ Jesus, and ... Read More

Psalm, Psalms 52:10, 11
Read More

Gospel, Luke 4:38-44
Leaving the synagogue he went to Simon's house. Now Simon's ... Read More

Saint of the Day

September 2 Saint of the Day

St. Ingrid of Sweden
September 2: Born in Skänninge, Sweden, in the 13th century, St. Ingrid lived ... Read More